Literature DB >> 8291733

Closed-circuit anesthesia with sevoflurane in humans. Effects on renal and hepatic function and concentrations of breakdown products with soda lime in the circuit.

H Bito1, K Ikeda.   

Abstract

BACKGROUND: Sevoflurane reacts with CO2 absorbents, resulting in the generation of breakdown products. The concentrations of sevoflurane breakdown products in a low-flow system within 5 h have been reported, but concentrations in low-flow anesthesia exceeding 5 h or in closed-circuit anesthesia have not. In this study, the breakdown products of sevoflurane in closed-circuit anesthesia exceeding 5 h were examined.
METHODS: Closed-circuit sevoflurane anesthesia was administered to ten patients. Laboratory tests of hepatic and renal function were performed before and after anesthesia. Gas samples were obtained from the inspiratory limb of the anesthesia circuit, and breakdown products were analyzed by gas chromatography. The temperature of the soda lime was measured during anesthesia.
RESULTS: Among the breakdown products of sevoflurane, two products, CF2 = C(CF3)-O-CH2F (compound A) and CH3OCF2CH(CF3)OCH2F (compound B), were detected. Compound A was detected in all measurements, and its concentration reached 19.5 +/- 5.4 ppm 1 h after anesthesia and decreased after 5 h. The highest concentration observed for compound A was 30.0 ppm. Compound B was detected in seven of the ten patients; its concentration was 0.17 +/- 0.37 ppm after 0.5 h of anesthesia and remained at similar concentrations thereafter. The highest mean temperature of the soda lime was 46.0 +/- 1.7 degrees C. Postanesthetic clinical laboratory tests showed no abnormalities in hepatic or renal function associated with anesthesia.
CONCLUSIONS: Two breakdown products were detected in the patients anesthetized with sevoflurane using a closed-circuit technique. No abnormalities were observed during anesthesia, and no evidence of hepatic or renal dysfunction was noted in postoperative laboratory tests.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8291733     DOI: 10.1097/00000542-199401000-00014

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  7 in total

Review 1.  Safety considerations in the use of drug combinations during general anaesthesia.

Authors:  E S Ransom; R A Mueller
Journal:  Drug Saf       Date:  1997-02       Impact factor: 5.606

2.  Renal toxicity of compound A with sevoflurane anesthesia: The benefits of sevoflurane appear to outweigh the risks.

Authors:  Osafumi Yuge
Journal:  J Anesth       Date:  1997-03       Impact factor: 2.078

Review 3.  Sevoflurance: approaching the ideal inhalational anesthetic. a pharmacologic, pharmacoeconomic, and clinical review.

Authors:  L Delgado-Herrera; R D Ostroff; S A Rogers
Journal:  CNS Drug Rev       Date:  2001

Review 4.  Sevoflurane. A review of its pharmacodynamic and pharmacokinetic properties and its clinical use in general anaesthesia.

Authors:  S S Patel; K L Goa
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

Review 5.  Renal toxicity with sevoflurane: a storm in a teacup?

Authors:  B A Gentz; T P Malan
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 6.  Clinical pharmacokinetics of sevoflurane.

Authors:  M Behne; H J Wilke; S Harder
Journal:  Clin Pharmacokinet       Date:  1999-01       Impact factor: 6.447

7.  Kidney function in living donors undergoing nephrectomy by sevoflurane or desflurane anesthesia.

Authors:  Min-Soo Kim; Jeong-Rim Lee; Myoung-Soo Kim; Sung-Yeon Ham; Seung-Ho Choi
Journal:  Yonsei Med J       Date:  2013-09       Impact factor: 2.759

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.